Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) dropped 6.6% during mid-day trading on Wednesday . The stock traded as low as $0.61 and last traded at $0.63. Approximately 697,025 shares traded hands during trading, an increase of 36% from the average daily volume of 512,195 shares. The stock had previously closed at $0.67.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on TVGN shares. Weiss Ratings restated a "sell (e+)" rating on shares of Tevogen Bio in a research report on Wednesday, October 8th. D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Tevogen Bio in a research report on Thursday, September 4th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $10.00.
View Our Latest Research Report on TVGN
Tevogen Bio Stock Performance
The business has a 50 day moving average price of $0.82 and a two-hundred day moving average price of $1.02. The company has a market cap of $123.77 million, a P/E ratio of -3.31 and a beta of -0.83.
Tevogen Bio (NASDAQ:TVGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 19th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.02.
Institutional Investors Weigh In On Tevogen Bio
A hedge fund recently bought a new stake in Tevogen Bio stock. Nuveen LLC acquired a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 90,253 shares of the company's stock, valued at approximately $97,000.
About Tevogen Bio
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
